DOCSLIB.ORG

INSIDE THIS ISSUE EXCLUSIVE Anthony Adams Kizzmekia Corbett

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
INSIDE THIS ISSUE EXCLUSIVE Anthony Adams Kizzmekia Corbett Feb/Mar, 2021 SMART PAGES SINCE 2006 DBUSINESSETR - POLITICS OI- COMMUNITYT “Building Business to Business and Business to Community Relationships” INSIDE THIS ISSUE EXCLUSIVE Anthony Adams Why I want to be Everyone’s Mayor in Detroit pg. 11 Kizzmekia Corbett Lead Scientific Researcher, Coronavirus Vaccine pg. 4 www.detroitsmartpages.com | [email protected] Commonly asked questions about COVID-19 VACCINES 1. What are the differences and second time, it really develops that (LNP) carrier, essential for efficient vaccine at an alternate site. similarities between the Moderna full, long term memory. delivery of the mRNA, were FDA If you have ever had a severe and Pfizer vaccines? 4. What are the common side approved only a couple years ago. reaction to the Pfizer or Moderna • Both vaccines are about 95% ef- effects of the vaccine? Additional vaccines for rabies, Zika COVID-19 vaccines, or any of their fective. Pfizer and Moderna had a The most common side effects and influenza remain under devel- components, you cannot receive fair and comparable spread of races that have been reported with the opment and it is likely we will see the vaccine. and ethnicities included in the clin- COVID-19 vaccine include: other mRNA vaccines approved in • If you have had an anaphylactic ical trials. There does not appear • Injection site pain the near future. reaction to any vaccine or in- to be any significant differences in • Tiredness 8. Will this be a once a year vaccine jectable, you cannot receive the vaccine effectiveness between the • Headache or once you have both doses will it COVID-19 vaccine at Beaumont at two brands. • Muscle pain be for life? this time without an approval/eval- • For the Pfizer vaccine, the first • Chills We don’t yet know how long the uation from an allergist. However, and second dose should be approx- • Joint pain protection from the vaccine will you can be evaluated by an allergist imately 21 days apart and is recom- • Fever last. Once more data is available, or immunologist to see if you can mended for ages 16 and up. • Injection site swelling we will be able to determine how safely receive the vaccine at an • For the Moderna vaccine, the first • Injection site redness frequently we will need booster alternate clinic. and second dose should be approx- • Nausea vaccine doses. The vaccine appointment may imately 28 days apart and is recom- • Feeling unwell be scheduled after your allergist mended for ages 18 and up. • Swollen lymph nodes 9. How long after administration of approves if you meet the state’s • Both vaccines have the same side 5. What are the side effects of the the second dose of the vaccine can distribution criteria. Please bring effects listed with the CDC. The second dose? we consider it to be fully effective? your allergist’s written approval to most common side effects include Based on the study data, some Protection begins building soon af- the vaccine appointment. tiredness, headache and chills. individuals may have somewhat in- ter the first dose, and studies sug- • If you have had any other kind • Pfizer’s vaccine must be kept at creased symptoms with the second gest maximum protection begins of anaphylactic reaction, such as much lower temperatures than the dose compared with the first. These about 7 to 14 days after the second to food or the environment, you Moderna vaccine. symptoms should still be manage- dose. can receive the vaccine at one of 2. How do COVID-19 mRNA able with simple over-the-counter 10. Do I need to continue wearing our vaccine clinics if you meet the vaccines work? interventions such as ibuprofen. a mask and social distancing after state’s distribution criteria. Howev- mRNA, or messenger RNA, is ge- 6. What if you’re asymptomatic I receive both doses of the vaccine? er, you will be asked to remain in netic material that contains in- and don’t know you’re COVID-19 It’s important for everyone to observation for 30 minutes instead structions for making proteins. positive and you receive the vac- continue using all the tools avail- of 15 minutes. mRNA vaccines for COVID-19 cine? What will happen? able to us to help stop this pandem- 12. I have had allergic reactions to contain synthetic mRNA. Inside CDC is recommending even those ic, like covering your mouth and vaccines in the past. Should I get the body, the mRNA enters human who have had COVID-19 and have nose with a mask, washing hands Moderna or Pfizer? cells and instructs them to produce antibodies receive the vaccine, so often, and staying at least 6 feet Severe allergic reactions from the “spike” protein found on the this is not a problem. However, we away from others. Experts need to either vaccine are very low risk and surface of SARS-CoV-2, the virus ask you wait 90 days after the first understand more about the pro- there shouldn’t need to be a prefer- that causes COVID-19. The body onset of symptoms to schedule tection that COVID-19 vaccines ence for one over the other due to recognizes the spike protein as an your first vaccination. provide before deciding to change allergies. According to the CDC, invader, and produces antibodies 7. I understand that the COVID-19 those recommendations. most of all severe allergic reactions against it. If the antibodies later en- vaccine is the first mRNA approved 11. If someone is vaccinated can occur within 15 minutes of vacci- counter the actual virus, they are vaccine in the U.S., but that they they still be a carrier of COVID-19 nation, which is when patients are ready to recognize and destroy it have been researching MRNA vac- and bring it into their household? in the observation area of the vac- before it causes illness. cines for decades. I would like to We are hopeful that vaccinated in- cine clinics. Allergic reactions to 3. Why did I need to get two doses get vaccinated, but I would like dividuals will be less likely to carry food or environmental causes are of the vaccine? What happens if I to know first why none of the oth- the virus that causes COVID-19; not a factor in getting vaccinated don’t get my second shot? er MRNA vaccines have been ap- however, additional studies are for COVID-19. There are some viruses and bacte- proved, but this one has. needed to confirm. 13. Can I choose which type of ria that we vaccinate against that We are fortunate that recent ad- What if I have allergies or have had vaccine I want when I make my one dose of the vaccine just doesn’t vances over the past few years an allergic reaction to a appointment? provide full immunity in order to allowed this technology to be vaccine in the past? The number and type of vac- prevent illness if you were to be immediately utilized to rapidly Thanks to new information, cines receives vary week to week, exposed to it, whereas priming the develop COVID-19 vaccines with Beaumont re-vamped the process depending on what the State of system allows your immune sys- very promising efficacy results for determining who can safely be Michigan sends. Therefore, you are tem to react to it once, create some without compromising safety. For vaccinated at one of our vaccine not able to select the type of vaccine memory and, when exposed to it a example, the lipid nanoparticle clinics, and who should receive the you receive when scheduling. www.detroitsmartpages.com FEBRUARY/MARCH 2021 | PAGE 2 W A Y N E C O U N T Y S E N I O R S Kizzmekia Corbett-Lead Scientist, Vaccine Research Center (VRC), Coronavirus Virus Kizzmekia “Kizzy” Shanta Cor- called Proj- viral immunologist, at the NIH. Her that messenger RNA (mRNA) encod- bett an American viral immunolo- ectSEED, research aims to uncover mecha- ing S protein could be used to excite gist at the Vaccine Research Center spent her nisms of viral pathogenesis and host the immune response to produce (VRC) at the National Institute of Al- summer immunity. She specifically focuses protective antibodies against corona- lergy and Infectious Diseases, Nation- holiday on development of novel vaccines virus disease 2019. To manufacture al Institutes of Health (NIAID NIH) working in for coronaviridae. Her early research and test the COVID-19 vaccine Cor- based in Bethesda, Maryland. Ap- research considered the development of Severe bett’s team partnered with Moderna, pointed to the VRC in 2014, she is cur- laborato- Acute Respiratory Syndrome (SARS) a biotechnology company, to rapidly rently the scientific lead of the VRC’s ries, one of and Middle East Respiratory Syn- enter animal studies. Subsequent- Coronavirus Team, with research ef- which was drome (MERS) vaccine anti- ly, the vaccine entered Phase 1 clin- forts aimed at propelling novel corona- at UNC’s gens. During this time, she identified ical trial only 66 days after the virus virus vaccines, including a COVID-19 Kenan Labs a simple way to make spike proteins sequence was released. The trial, vaccine. In December 2020, the Insti- with organic chemist James Mor- that are stabilized in a conformation to be completed in at least 45 peo- tute’s Director Anthony Fauci said: kin. In 2005, she was a summer intern that renders them more immunogenic ple, is a dose escalation study in the “Kizzy is an African American sci- at Stony Brook University in Gloria and manufacturable, in collaboration form of two injections separated by entist who is right at the forefront Viboud’s lab where she studied Yersin- with researchers at Scripps Research 28 days.
Load more

Recommended publications
  • Session 2: Black Women and Sexual and Reproductive Health August 6
    8/6/20 Session 2: Black Women and Sexual and Reproductive Health August 6, 2020 1 This program is funded wholly, or in part, by the Government of the District of Columbia, Department of Health, HIV/AIDS, Hepatitis, STI and TB Administration (HAHSTA). 2 1 8/6/20 Learning Objectives • Discuss the unique perspectives of health inequalities on the lives of Black youth-, young adult-, middle-, and older-aged Black women • Describe the common socioeconomic determinants associated with lack of access to health care and vulnerability to intimate partner violence in Black women of reproductive age. • List the health inequities that drive disparate rates of HIV and STIs among Black women across the life course. • Describe the comorbidities in older Black who are or have experienced menopause. • Detail the health care access barriers created by provider bias and stigma. • Analyze the factors that foster resilience in Black women across the lifespan. 3 Moderators Hanna Tessema, DrPH(c), MPH, MSW Lecturer, George Washington University, Milken Institute School of Public HealthHIV Lisa Frederick Capacity Building Manager, HealthHIV 4 2 8/6/20 Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
    [Show full text]
  • View (E39) Richard Ofori-Asenso, Ella Zomer, Andrea Curtis, Andrew Tonkin, Mark Nelson, Manoj Gambhir, Danny Liew, Sophia Zoungas
    JMIR Research Protocols Ongoing Trials, Grant Proposals, Formative Research, Methods, Early Results Volume 6 (2017), Issue 3 ISSN: 1929-0748 Contents Protocols Telerehabilitation Versus Traditional Care Following Total Hip Replacement: A Randomized Controlled Trial Protocol (e34) Mark Nelson, Michael Bourke, Kay Crossley, Trevor Russell. 3 Bioengineered Temporomandibular Joint Disk Implants: Study Protocol for a Two-Phase Exploratory Randomized Preclinical Pilot Trial in 18 Black Merino Sheep (TEMPOJIMS) (e37) David Ângelo, Florencio Monje, Raúl González-García, Christopher Little, Lisete Mónico, Mário Pinho, Fábio Santos, Belmira Carrapiço, Sandra Gonçalves, Pedro Morouço, Nuno Alves, Carla Moura, Yadong Wang, Eric Jeffries, Jin Gao, Rita Sousa, Lia Neto, Daniel Caldeira, Francisco Salvado. 12 Home-Based Intervention Program to Reduce Food Insecurity in Elderly Populations Using a TV App: Study Protocol of the Randomized Controlled Trial Saúde.Come Senior (e40) Ana Rodrigues, Maria Gregório, Pierre Gein, Mónica Eusébio, Maria Santos, Rute de Sousa, Pedro Coelho, Jorge Mendes, Pedro Graça, Pedro Oliveira, Jaime Branco, Helena Canhão. 22 Writing for Health: Rationale and Protocol for a Randomized Controlled Trial of Internet-Based Benefit-Finding Writing for Adults With Type 1 or Type 2 Diabetes (e42) Joanna Crawford, Kay Wilhelm, Lisa Robins, Judy Proudfoot. 36 Automated Adherence Reminders for High Risk Children With Asthma: A Research Protocol (e48) Sarah Adams, Michelle Leach, Chris Feudtner, Victoria Miller, Chén Kenyon. 52 Effectiveness
    [Show full text]
  • TITLE: PREP for WOMEN: PREVENTION OPPORTUNITIES in CLINICAL PRACTICE Speaker: Oni J
    Clinical Education Initiative [email protected] TITLE: PREP FOR WOMEN: PREVENTION OPPORTUNITIES IN CLINICAL PRACTICE Speaker: Oni J. Blackstock, MD 3/15/2017 PrEP for Women: Prevention Opportunities in Clinical Practice [video transcript] [00:00:00] [Intro music] - [Jessica] Good afternoon and welcome to this month in HIV. Our March presentation is PrEP for Women: Prevention Opportunities in Clinical Practice. And will be presented by Dr. Oni Blackstock, who is an assistant professor of medicine and a primary care physician and researcher at Montefiore Medical Center in Albert Einstein College of Medicine in the Bronx in New York City. My name is Jessica Steinke. I'm the program coordinator for HIV/AIDS education and training department with the Mount Sinai Institute for Advanced Medicine. So before I officially introduce our speaker, I would like to thank our funders, the New York State Department of Health AIDS Institute, Clinical Education Initiative, and the Mount Sinai Institute for Advanced Medicine served as a co-sponsor of this Month in HIV. A couple housekeeping notes. For the duration of today's presentation, all lines will be muted to ensure that there will be no distractions during Dr. Blackstock's presentation. At the end of the presentation we will unmute all phone lines for the Q&A part. However, if you do not have a question for the presenter or if you are not presently speaking, we do ask that you please mute your phone line to limit distractions. And please do mute it rather than put your line on hold as sometimes that hold music starts which can disturb the webinar also.
    [Show full text]
  • Ending HIV in America: Policy and Program Insights from Local Health
    Ending HIV in America Policy and Program Insights From Local Health Agencies and Providers SEPTEMBER 2019 STAFF G. William Hoagland Tyler Barton Senior Vice President Research Analyst Anand Parekh, M.D. Collier Fernekes Chief Medical Advisor Project Assistant Kate Cassling Charles Holmes, M.D. Senior Manager Consultant Morgan Bailie Naomi Seiler, J.D. Project Associate Consultant ACKNOWLEDGMENTS The Bipartisan Policy Center would like to thank Gilead Sciences, Inc. and The Elizabeth Glaser Pediatric AIDS Foundation for their generous support. BPC also thanks the state, county, and city health department officials and HIV service providers who generously gave their time to participate in interviews to inform this work. Special thanks to Patrick Sullivan of AIDSVu at Emory University for his expert guidance regarding national and local HIV data and mapping. DISCLAIMER This report is the product of BPC staff. The findings and considerations expressed herein do not necessarily represent the views or opinions of the Bipartisan Policy Center’s founders, its board of directors, or the individuals who participated in interviews, who are listed in the Appendix. 2 bipartisanpolicy.org 4 Executive Summary 6 Introduction 10 Report Objectives and Methods 10 Objectives 10 Methods 11 Jurisdiction and Provider Profiles 11 Bronx, New York, and Montefiore Medical Center 13 Clark County, Nevada, and Aid for AIDS Nevada 14 Duval County, Florida, and Jacksonville Area Sexual Minority Youth Network (JASMYN) 15 Kansas City, Missouri, and KC CARE Health Center 17 Montgomery, Alabama, and Medical Advocacy and Outreach (MAO) 18 Richmond, Virginia, and Capital Area Health Network 19 Seattle, Washington, and The Madison Clinic at Harborview Medical Center 21 Scott County, Indiana, and Dr.
    [Show full text]
  • Get Continuing Education Accreditation
    Get Continuing Education (CE): PrEP and PEP Action Kit for Women #SS4109 PROGRAM DESCRIPTION: The PrEP and PEP Action Kit for Women is designed to provide clinicians with the background and resources needed to support informed discussion of biomedical HIV prevention with their patients and to assist in the incorporation of biomedical HIV prevention into their clinical practice. OBJECTIVES: At the conclusion of the session, the participant will be able to: 1. Describe how to take a thorough sexual history 2. Describe the current sexually transmitted infection (STI) screening practices for sexually active patients according to CDC guidelines 3. Discuss current recommendations for post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) to prevent HIV infection FACULTY/CREDENTIALS: Dr. Oni Blackstock, MD MHS, Assistant Commissioner, Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene Dr. Julie Myers, MD MPH, Director of HIV Prevention, Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene ORIGINATION DATE: October 14, 2018 RENEWAL DATE: October 14, 2020 EXPIRATION DATE: October 14, 2022 URL: https://www1.nyc.gov/site/doh/providers/resources/public-health-action-kits-prep-pep.page HARDWARE/SOFTWARE: Computer Hardware; Internet connection; Browser MATERIALS: PrEP and PEP Action Kit for Women TARGET AUDIENCE: Physicians, Doctors of Osteopathic Medicine, Registered Nurses, Nurse Practitioners, Nurse Technicians, Physician Assistants, Medical Students PREREQUISITES: The target audience should have a basic understanding of HIV and how it is transmitted FORMAT: Enduring materials CONTACT INFORMATION: Dr. Zoe Edelstein, Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene, (347) 396-7650 Updated: 05.19.2020 Page 1 of 3 ACCREDITATION STATEMENTS: In support of improving patient care, this activity has been planned and implemented by Centers for Disease Control and Prevention and New York City Department of Health and Mental Hygiene.
    [Show full text]
  • 2019 Ending the Epidemic Summit Program
    2019 Ending the Epidemic Summit MAINTAINING THE MOMENTUM, EXPANDING THE VISION! December 3, 2019 from 9:00 am to 6:00 pm December 4, 2019 from 9:00 am to 3:00 pm Empire State Plaza Convention Center and The Egg Albany, New York The New York State Department of Health AIDS Institute (NYSDOH AI) is hosting the fourth annual Ending the Epidemic Summit on December 3-4, 2019 at the Empire State Plaza Convention Center and accompanying meeting rooms. The 2019 Ending the Epidemic Summit is intended to bring key stakeholders to one forum to share Ending the Epidemic implementation eorts focusing on the theme of Maintaining the Momentum, Expanding the Vision! Webcast QR code for CART Services. 2 Ending the Epidemic Summit Agenda Outline Tuesday, December 3, 2019 8:00 am Registration Opens in Front of Meeting Room 6 9:00 am – 11: 00 am Webcast 9:00 am Welcoming Remarks and Ending The Epidemic (ETE) Research Panel, The Egg, Hart Theatre 11:00 am Networking Lunch, The Egg, Hart Lounge and Meeting Room 6 11:30 am Poster Presentations, Base of The Egg 1:00 pm Breakout Sessions, Empire State Plaza - Meeting Rooms • Increase in Hepatitis C and Congenital Syphilis: The Other Consequences of the Opioid Epidemic • Community-University Collaborations in HIV Prevention Research: The Role of Student Engagement in the Research Process • Talk ETE: Family Feud Meets Jeopardy! • Structural Interventions to End the Epidemic: Where is the Evidence? Evaluation Research to Document Your Program’s Success 2:30 pm – 3:30 pm Webcast 2:30 pm World AIDS Day Commissioner’s Special Recognition Awards Ceremony, recognizing individuals for their commitment and contributions to improving and promoting the health and well-being of all New Yorkers.
    [Show full text]
  • Download As A
    PERSAD (1).DOCX (DO NOT DELETE) 8/9/21 4:47 PM ALLOCATING MEDICINE FAIRLY IN AN UNFAIR PANDEMIC Govind Persad* America’s COVID-19 pandemic has both devastated and disparately harmed minority communities. How can the allocation of scarce treatments for COVID-19 and similar public health threats fairly and legally respond to these racial disparities? Some have proposed that members of racial groups who have been especially hard-hit by the pandemic should receive priority for scarce treatments. Others have worried that this prioritization misidentifies racial disparities as reflecting biological differences rather than structural racism, or that it will generate mistrust among groups who have previously been harmed by medical research. Still others complain that such prioritization would be fundamentally unjust. I argue that, to pass muster under current law, policymaking in this area must recognize a cru- cial distinction: prioritizing minority communities without regard to indi- vidual race is typically legal, but prioritizing individuals on the basis of their racial identity is likely not. I also explain how prioritization on the basis of Native American status is allowable and legally distinct from pri- oritization on the basis of race. In Part II, I provide a brief overview of current and proposed COVID- 19 treatments and identify documented or likely scarcities and disparities in access. In Part III, I argue that randomly allocating scarce medical in- terventions, as some propose, will not effectively address disparities: it both permits unnecessary deaths and concentrates those deaths among people who are more exposed to infection. In Part IV, I explain why using individ- ual-level racial classifications in allocation is precluded by current Su- preme Court precedent.
    [Show full text]